Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ziftomenib by Kura Oncology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Ziftomenib by Kura Oncology for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Ziftomenib by Kura Oncology for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to...
Ziftomenib by Kura Oncology for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Ziftomenib is under clinical development by Kura Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Tipifarnib by Kura Oncology for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Tipifarnib is under clinical development by Kura Oncology and currently in Phase III for Peripheral T-Cell Lymphomas (PTCL). According to...
KO-2806 by Kura Oncology for Colorectal Cancer: Likelihood of Approval
KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
KO-2806 by Kura Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Non-Small Cell Lung Cancer. According to...
KO-2806 by Kura Oncology for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
KO-2806 by Kura Oncology for Metastatic Renal Cell Carcinoma: Likelihood of Approval
KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Metastatic Renal Cell Carcinoma. According to...
KO-2806 by Kura Oncology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
KO-2806 is under clinical development by Kura Oncology and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
Tipifarnib by Kura Oncology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Tipifarnib by Kura Oncology for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Tipifarnib is under clinical development by Kura Oncology and currently in Phase II for Recurrent Head And Neck Squamous Cell...